Treatment of Opioid Use Disorder: Waiver Qualifying - MOC - Monday, March 29, 2021

Product not yet rated

Includes a Live Event on 03/29/2021 at 8:00 AM (EDT)

  • Register
    • Non-Member - Free!
    • Regular Member - Free!
    • Retired - Free!
    • Early Career Physician - Free!
    • Resident - Free!
    • Student - Free!
    • Associate - Free!
    • ASAM Staff - Free!
    • International Member - Free!
    • Emeritus Member - Free!
    • Provisional Member - Free!
    • Fellow Member - Free!
    • Honorary Member - Free!
    • CRT Member - Free!

image

Host: Michigan Opioid Collaborative

Monday, March 29, 2021 | 8:00 am - 5:00 pm ET

Location: Ann Arbor, MI

Live Virtual Course

Overview

Welcome to the ASAM Treatment of Opioid Use Disorder Course. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training. 

Getting Started

Please log in to begin. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.

Learning Objectives 

Module 1 

  1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
  2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
  3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
  4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
  5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

Module 2

  1. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
  2. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
  3. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

Module 3

  1. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
  2. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
  3. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

Overall

Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

Key:

Complete
Failed
Available
Locked
Complete Pre-Course Survey
2 Questions
2 Questions Please answer the following
Attend Live Virtual Course
03/29/2021 at 8:00 AM (EDT)   |  480 minutes
03/29/2021 at 8:00 AM (EDT)   |  480 minutes
Complete Live Portion Evaluation
17 Questions
17 Questions Please complete the evaluation to claim CME.
Download CME Certificate
Up to 8.00 medical credits available  |  Certificate available
Up to 8.00 medical credits available  |  Certificate available This session has been approved for 8 AMA PRA Category 1 Credits. Participants should claim only the credits commensurate with the extent of their participation in the activity.

Target Audience

  1. Physicians, Nurse Practitioners, Physician Assistants, Certified Nurse Midwives, Certified Registered Nurse Anesthetists, and Clinical Nurse Specialists who wish to obtain a waiver to prescribe buprenorphine in an office-based setting for opioid use disorder.
  2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

Cara Poland, MD, MEd, DFASAM

MD, MEd, DFASAM

Cara Poland, MD, MEd, DFASAM was trained in internal medicine at St. Joseph Mercy Hospital in Ann Arbor, Michigan and in addiction medicine at Boston Medical Center in Boston, Massachusetts. She has an interest in education physicians and physicians-in-training to improve care for patients with substance abuse and alcohol disorders. She is interested in medical student curriculum development and assessment, student well-being and identifying ways to improve the process of medical training. She sits on the Board of Directors for the Red Project and multiple leadership boards of various professional societies such as the Midwest Society of General Internal Medicine and American Society of Addiction Medicine. She is currently a physician at Spectrum Health's Center for Integrative Medicine.

Christopher Frank

MD, PhD

Dr. Frank earned his undergraduate degree at the University of Michigan and graduated from Johns Hopkins University School of Medicine with an M.D. and a Ph.D. in molecular biology. He completed his family medicine residency at the University of Wisconsin in a specialized program designed to prepare family physicians to work in rural communities. Prior to joining the University of Michigan Department of Family Medicine, he worked eight years as a full-scope family physician in a Health Professional Shortage Area in Washington State, and as the health officer/medical director of a local health department. He taught medical students and residents as a clinical assistant professor in the University of Washington Department of Family Medicine. He also chaired a broad coalition that developed a regional response to the opioid crisis, served on the Washington State Board of Health, and led an innovative program that required mandatory reporting of fatal and non-fatal overdoses so patients could be quickly enrolled in evidence-based treatment and prevention services. His clinical interests include comprehensive primary care, including obstetrics, prevention and treatment of opioid-use disorders, and medical education. He is a waivered buprenorphine prescriber and treats patients with a range of substance-use disorders, including women struggling with opioid-use disorders during pregnancy. In addition to working with individual patients, he has been a supervising physician within a nurse-managed MAT program, and has worked on system-changes to improve access to treatment for patients in acute care settings and the criminal justice system.

Credits and Disclosures


ACCME Accredited with Commendation

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NAADAC, the Association for Addiction Professionals

This activity has been approved by the American Society of Addiction Medicine, as a NAADAC Approved Education Provider, for educational credits. NAADAC Provider #295, ASAM is responsible for all aspects of the programming.

California Association for Drug/Alcohol Educators (CAADE)

This educational program is approved by CAADE: #CP40 999 1222

California Association of DUI Treatment Centers (CADTP)

This educational program is approved by CADTP: #205

California Consortium of Addiction Programs and Professionals (CCAPP)

This educational program is approved by CCAPP: #OS-20-330-1222

Continuing Education Credits (CEUs)

Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

Maintenance of Certification


American Board of Preventive Medicine (ABPM)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

American Board of Anesthesiology (ABA)

This activity contributes to the CME component of the American Board of Anesthesiology’s redesigned Maintenance of Certification in Anesthesiology TM (MOCA®) program, known as MOCA 2.0®.

American Board of Pediatrics (ABP)

Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn a maximum of 8 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

American Board of Internal Medicine (ABIM)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credits.

American Board of Surgery (ABS)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and/or Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit

American Board of Psychiatry and Neurology (ABPN)

Successful completion of this CME activity can be used to satisfy the American Board of Psychiatry and Neurology’s (ABPN) CME requirement for Maintenance of Certification program.

American Board of Addiction Medicine (ABAM)

Successful completion of this activity can be used to satisfy the American Board of Addiction Medicine (ABAM) for Tmoc as credits towards ABAM LLSA Part II requirements.

CME Reviewer and Disclosure Information


ASAM CME Committee Reviewer

Benjamin Bearnot, MD - Does Disclose

• We The Village, Inc, Clinical Condition: Opioid Use Disorder, CRAFT support, Consultant/Advisory Board 

• Halcyon Health, Clinical Condition: Opioid Use Disorder, Recovery Coaching, Consultant/Advisory Board

Program Planning Committee, CME Committee, Medical Education Council (MEC), and Faculty Disclosure Information

In accordance with disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME activities. These policies include resolving all possible conflicts of interest for the Planning Committees, CME Committee, MEC, and Faculty. All activity Planning Committee members and Faculty have disclosed relevant financial relationship information. The ASAM CME Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

Faculty and Planning Committee


Faculty Disclosure Information



Planning Committee Disclosure Information

Melissa Weimer, DO, MCR, FASAM – Does Disclose

  • Path CCM, Inc, Consultant/Advisory Board, Clinical Condition: SUD, Consultant/Advisory Board

Deanna Wilson, MD, MPH– No Relevant Financial Disclosures
Pittsburgh, PA

Alta DeRoo, MD, FASAM – Does Disclose

  • Indivior, Speaker honorarium
  • Alkermes, Speaker honorarium

Soraya Azari, MD – No Relevant Financial Disclosures
San Francisco, CA

Kristen Smith, DNP, FNP-C, AAHIVS – No Relevant Financial Disclosures
Atlanta, GA

Matt Tierney, NP, CNS – No Relevant Financial Disclosures
San Francisco, CA

Debra Newman, PA-C, MPAS, MPH – No Relevant Financial Disclosures
Santa Fe, NM

Edwin A. Salsitz, MD, DFASAM – No Relevant Financial Disclosures
New York, NY

How to Claim CME

  1. Fill out the survey by clicking the “Fill out Survey” button in the box titled “Complete Live Portion Evaluation” at the end of the training.
    Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window.
  2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)
  3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”
  4. Choose the type of credit (Physician or Non-physician) and click submit.
  5. Click the button “View/Print Certificate” to save or print your certificate
    Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)

How to Apply for a Waiver

Physicians

  • Fill out the Waiver Notification Form on SAMHSA’s website. You can upload a copy of your training certificate(s) directly to the Waiver Notification Form.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Other Approved Prescribers

Apply

NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

Qualify

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
  • Complete no less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD
  • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

  • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
  • Complete not less than 24 hours of appropriate education through a qualified provider
  • Through other training or experience, demonstrate the ability to treat and manage OUD  
  • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with: